225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells, has shown remarkable therapeutic efficacy in heavily pretreated mCRPC patients (7–11). This evidence concerns the gene FOLH1 and prostate carcinoma.